BCR–ABL1 T315I mutation, a negative prognostic factor for the terminal phase of chronic myelogenous leukemia treated with first- and second-line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplant as the treatment of choice

Ciprian TomuleasaDepartment of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania;Research Center for Functional Genomics and Translational Medicine, Cluj Napoca, RomaniaCorrespondence[email protected] [email protected]

Delia DimaDepartment of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania

Ioana FrincDepartment of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania

Mariana PatiuDepartment of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania

Bobe PetrushevResearch Center for Functional Genomics and Translational Medicine, Cluj Napoca, Romania

Andrei CucuianuDepartment of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania;Department of Hematology, Iuliu Hatieganu University, Cluj Napoca, Romania

Ioana Berindan-NeagoeResearch Center for Functional Genomics and Translational Medicine, Cluj Napoca, Romania;Department of Genetics, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania

show all

"BCR–ABL1 T315I mutation, a negative prognostic factor for the terminal phase of chronic myelogenous leukemia treated with first- and second-line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplant as the treatment of choice." Leukemia & Lymphoma, 56(2), pp. 546–547

Potential conflict of interest:

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

BCR–ABL1 T315I mutation, a negative prognostic factor for the terminal phase of chronic myelogenous leukemia treated with first- and second-line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplant as the treatment of choice

Information for

Open access

Opportunities

Help and information

BCR–ABL1 T315I mutation, a negative prognostic factor for the terminal phase of chronic myelogenous leukemia treated with first- and second-line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplant as the treatment of choice

Potential conflict of interest:

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature